诱导型一氧化氮合酶与疾病  

Inducible Nitric Oxide Synthase and Its Relevance to Diseases

作　　者：章丹丹[1] 刘俊[1] Ferid Murad 卞卡[1] 

机构地区：[1]上海中医药大学穆拉德中药现代化研究中心,上海201203

出　　处：《现代生物医学进展》2007年第10期1571-1573,1577,共4页Progress in Modern Biomedicine

基　　金：国家教育部重点科研项目(05ZZ11);上海市教委高校一氧化氮与炎症医学E研究院计划(E-04010);上海市教委项目(05Jg05053);上海市科委基础研究重点项目(05JC14056)

摘　　要：炎症是众多疾病如自体免疫紊乱、神经退行性病变、心血管疾病和癌症发展的病理机制,诱导型一氧化氮合酶在炎症过程中被诱导表达,产生过量的一氧化氮,引发炎症级联反应,进而导致以上多种疾病发生。抑制诱导型一氧化氮合酶表达在体内体外实验及临床使用中均体现抗炎效果和症状改善。本文综述了诱导型一氧化氮合酶在炎症过程中诱导表达及与各类重大疾病联系的最新进展,并展望了诱导型一氧化氮合酶抑制剂作为抗炎治疗策略的前景。Inflammatory reaction has been considered as a critical factor in many human diseases, including neurodegenerative conditions, autoimmune disorders, cardiovascular diseases, and cancer. In inflammatory processes, inducible NO synthase （iNOS）are induced to produce excessive nitric oxide （NO） and lead to cascade reactions of inflammation and above-mentioned many diseases. NO is a biological mediator that synthesized from L-arginine using NADPH and molecular oxygen by NO Synthase. Though NO has physiological mechanisms in cardiovascular, nervous and immunological systems as host defense effectors, NO derived by iNOS in inflammation has cell toxicity and seems to be involved in the pathology of different human diseases. INOS high levels of expression has been considered as bio-marker of inflammatory diseases such as atherosclerosis, rheumatoid arthritis, diabetes, multiple sclerosis, cancer. Inhibiting iNOS expression has opened new interesting perspectives in the treatment of these inflammatory diseases because iNOS inhibitors has been shown as a potent therapeutic agent of inflammation in internal and external experiments as well as in animal models and clinic trials and its prevention is a target for design of new drugs. This review focuses on recent research achievements regarding the relationship between iNOS and inflammatory mechanism based on diseases ,with the perspective of using iNOS inhibitors as therapeutic strategy for inflammation involved diseases.

关 键 词：诱导型一氧化氮合酶 一氧化氮 炎症反应 疾病 

分 类 号：R318.04[医药卫生—生物医学工程]